These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

75 related items for PubMed ID: 8747885

  • 1. Mg2+ enhances high affinity [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding and guanine nucleotide modulation of serotonin-1a receptors.
    DeVinney R, Wang HH.
    J Recept Signal Transduct Res; 1995 Apr; 15(5):757-71. PubMed ID: 8747885
    [Abstract] [Full Text] [Related]

  • 2. Potency of 5-hydroxytryptamine1a agonists to inhibit adenylyl cyclase activity is a function of affinity for the "low-affinity" state of [3H]8-hydroxy-N,N-dipropylaminotetralin ([3H]8-OH-DPAT) binding.
    Chamberlain J, Offord SJ, Wolfe BB, Tyau LS, Wang HL, Frazer A.
    J Pharmacol Exp Ther; 1993 Aug; 266(2):618-25. PubMed ID: 8355195
    [Abstract] [Full Text] [Related]

  • 3. [Multiple [3H]8-hydroxy-2-(di-n-propylamino)-tetralin binding sites in rat brain: modulation by GTP and cations].
    Yokota N, Yamawaki S, Hayakawa H, Yoshida R, Sarai K.
    Yakubutsu Seishin Kodo; 1989 Jun; 9(2):197-206. PubMed ID: 2530729
    [Abstract] [Full Text] [Related]

  • 4. [3H]WB4101 labels the 5-HT1A serotonin receptor subtype in rat brain. Guanine nucleotide and divalent cation sensitivity.
    Norman AB, Battaglia G, Creese I.
    Mol Pharmacol; 1985 Dec; 28(6):487-94. PubMed ID: 2867462
    [Abstract] [Full Text] [Related]

  • 5. The GTP-insensitive component of high-affinity [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding in the rat hippocampus corresponds to an oxidized state of the 5-hydroxytryptamine1A receptor.
    Emerit MB, Miquel MC, Gozlan H, Hamon M.
    J Neurochem; 1991 May; 56(5):1705-16. PubMed ID: 1826520
    [Abstract] [Full Text] [Related]

  • 6. Modulation of 5-hydroxytryptamine1A receptor density by nonhydrolyzable GTP analogues.
    Harrington MA, Peroutka SJ.
    J Neurochem; 1990 Jan; 54(1):294-9. PubMed ID: 2136705
    [Abstract] [Full Text] [Related]

  • 7. Heterogeneity of cortical and hippocampal 5-HT1A receptors: a reappraisal of homogenate binding with 8-[3H]hydroxydipropylaminotetralin.
    Nénonéné EK, Radja F, Carli M, Grondin L, Reader TA.
    J Neurochem; 1994 May; 62(5):1822-34. PubMed ID: 8158133
    [Abstract] [Full Text] [Related]

  • 8. Detection of the 5-HT1A receptor and 5-HT1A receptor mRNA in the rat bowel and pancreas: comparison with 5-HT1P receptors.
    Kirchgessner AL, Liu MT, Howard MJ, Gershon MD.
    J Comp Neurol; 1993 Jan 08; 327(2):233-50. PubMed ID: 8425944
    [Abstract] [Full Text] [Related]

  • 9. Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist.
    De Vry J, Schohe-Loop R, Heine HG, Greuel JM, Mauler F, Schmidt B, Sommermeyer H, Glaser T.
    J Pharmacol Exp Ther; 1998 Mar 08; 284(3):1082-94. PubMed ID: 9495870
    [Abstract] [Full Text] [Related]

  • 10. [3H]8-OH-DPAT binding and serotonin content in rat cerebral cortex after acute fluoxetine, desipramine, or pargyline.
    Carli M, Afkhami-Dastjerdian S, Reader TA.
    J Psychiatry Neurosci; 1996 Mar 08; 21(2):114-22. PubMed ID: 8820177
    [Abstract] [Full Text] [Related]

  • 11. [3H]dihydroergotamine as a high-affinity, slowly dissociating radioligand for 5-HT1B binding sites in rat brain membranes: evidence for guanine nucleotide regulation of agonist affinity states.
    Hamblin MW, Ariani K, Adriaenssens PI, Ciaranello RD.
    J Pharmacol Exp Ther; 1987 Dec 08; 243(3):989-1001. PubMed ID: 2826763
    [Abstract] [Full Text] [Related]

  • 12. Effects of sulfhydryl-modifying reagents, 3-nitro-2-pyridinesulfenyl compounds, on the coupling between inhibitory receptors and GTP-binding proteins Gi/Go in rat brain membranes.
    Kitamura Y, Imai S, Matsueda R, Nomura Y.
    Mol Pharmacol; 1990 Aug 08; 38(2):184-91. PubMed ID: 2166901
    [Abstract] [Full Text] [Related]

  • 13. Allosteric modulation of 5-HT(1A) receptors by zinc: Binding studies.
    Barrondo S, Sallés J.
    Neuropharmacology; 2009 Feb 08; 56(2):455-62. PubMed ID: 18951909
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.